| Members |
targetComponentId |
| Therapeutic injection of botulinum toxin |
Injection of botulinum toxin (procedure) |
| Therapeutic injection of sinus tract |
Injection of substance into fistula (procedure) |
| Therapeutic prescription |
Prescription given (situation) |
| Therapeutic prescription NOS |
Prescription given (situation) |
| Therapeutic prescription NOS (situation) |
Prescription given (situation) |
| proctoscopie thérapeutique |
Proctoscopy |
| Therapeutic proctoscopy NOS |
Proctoscopy |
| œsophagoscopie rigide thérapeutique |
Rigid esophagoscopy |
| Thermoactinomyces candidus |
Thermoactinomyces vulgaris |
| Thermoactinomyces sacchari |
Laceyella sacchari (organism) |
| Thermoactinomyces thalpophilus |
Laceyella sacchari (organism) |
| Thermography - lymph nodes |
Lymph gland thermography |
| Phylum Thermomicrobia (organism) |
Class Thermomicrobia (organism) |
| Thermomonospora formosensis |
Actinomadura formosensis (organism) |
| Thermomycolin (substance) |
Thermomycolin |
| Thiamine preparation allergy |
Allergy to thiamine (finding) |
| Thiazole dye |
Thiazole (substance) |
| Thigh flap |
Flap (substance) |
| Thigh random pattern flap |
Random pattern flap |
| Thigh sprain |
Sprain of hip |
| Thinning |
Decreased thickness |
| Thioether hydrolase |
Thioether hydrolase |
| Thiolester hydrolase |
Thiolester hydrolase |
| Thioridazine 10mg/5mL syrup (product) |
Thioridazine 2 mg/mL oral solution |
| Thioridazine 50mg/5mL conventional release oral solution (product) |
Product containing precisely thioridazine hydrochloride 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Thioridazine 50mg/5mL s/f oral solution (product) |
Product containing precisely thioridazine hydrochloride 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Thioridazine hydrochloride 30mg/ml conventional release oral solution |
Thioridazine 30 mg/mL oral solution |
| Thioridazine hydrochloride 30mg/ml oral concentrate (product) |
Thioridazine 30 mg/mL oral solution |
| Thiothixene hydrochloride 5mg powder for injection solution vial (product) |
Thiothixene only product in parenteral dose form |
| Thiothixene hydrochloride 5mg/mL oral solution (product) |
Thiothixene 5 mg/mL oral solution |
| Third degree atrioventricular block |
bloc atrioventriculaire complet (trouble) |
| Third diphtheria and tetanus double vaccination |
Administration of third dose of diphtheria and tetanus vaccine |
| Third diphtheria and tetanus double vaccination |
Administration of third dose of diphtheria and tetanus vaccine |
| Third diphtheria, pertussis and tetanus triple vaccination |
Administration of third dose of diphtheria, pertussis, and tetanus vaccine |
| Thoracic mesothelioma TNM finding (finding) |
American Joint Committee on Cancer allowable value |
| Thoracic somatic dysfunction (finding) |
Somatic dysfunction of thoracic region (finding) |
| Thorny headed worm |
Phylum Acanthocephala (organism) |
| Threatened abortion (antepartum) (disorder) |
menace de fausse couche (trouble) |
| Threatened abortion - delivered |
menace de fausse couche (trouble) |
| Threatened abortion, unspecified as to episode of care |
menace de fausse couche (trouble) |
| Throat anti-infective preparation (product) |
Product manufactured as oromucosal dose form (product) |
| Thrombophilia due to acquired protein C deficiency (disorder) |
Acquired protein C deficiency (disorder) |
| Thrombophilia due to acquired protein S deficiency (disorder) |
Acquired protein S deficiency |
| Thrombosis of renal vein |
Thrombosis of renal vein |
| Thumb pulp flap |
Flap (substance) |
| Thymoma - category (morphologic abnormality) |
Thymoma |
| Thymoma |
Thymoma of uncertain behaviour |
| Thymoma, type A |
Thymoma, type A, malignant |
| Thymoma, type AB |
Thymoma, type AB, malignant |
| Thymoma, type B1 |
Thymoma, type B1, malignant |
| Thymoma, type B2 |
Thymoma, type B2, malignant |
| Thymoma, type B3 |
Thymoma, type B3, malignant |
| Thymosin alpha 1 1.6mg powder for conventional release solution for injection vial |
Product containing only thymalfasin (medicinal product) |
| Thymosin alpha 1 1.6mg powder for injection solution vial + diluent (product) |
Product containing only thymalfasin (medicinal product) |
| Thymoxamine 0.5% conventional release eye drops (product) |
Product containing only moxisylyte in ocular dose form (medicinal product form) |
| Thymoxamine 0.5% preservative-free eye drops (product) |
Product containing only moxisylyte in ocular dose form (medicinal product form) |
| Thyroid TNM finding (finding) |
American Joint Committee on Cancer allowable value |
| Thyroid eye disease with exophthalmos (disorder) |
Exophthalmos due to thyroid eye disease (disorder) |
| Thyroid eye disease with strabismus (disorder) |
Exophthalmos due to thyroid eye disease (disorder) |
| Thyroid gland excision |
Thyroidectomy |
| Thyroid related antibody (substance) |
Thyroid antibody |
| Thyrotropin alfa 0.9mg/mL powder for injection solution vial (product) |
Thyrotrophin only product |
| Thyrotropin alfa 1.1mg/vial powder (product) |
Thyrotrophin only product |
| Thyroxine sodium 100micrograms tablet (product) |
Levothyroxine sodium anhydrous 100 microgram oral tablet |
| Thyroxine sodium 25micrograms tablet (product) |
Product containing precisely levothyroxine sodium anhydrous 25 microgram/1 each conventional release oral tablet (clinical drug) |
| Thyroxine sodium 50micrograms tablet (product) |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
| Ticarcillin 3g/clavulanic acid 100mg powder for injection solution vial (product) |
Product containing precisely clavulanic acid (as clavulanate potassium) 100 milligram and ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Ticarcillin disodium 1g powder for injection solution vial (product) |
Product containing precisely ticarcillin (as ticarcillin disodium) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Ticarcillin disodium 20g powder for injection solution vial (product) |
Product containing precisely ticarcillin (as ticarcillin disodium) 20 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Ticarcillin disodium 3g powder for injection solution vial (product) |
Product containing precisely ticarcillin (as ticarcillin disodium) 3 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Tiludronate disodium (product) |
acide tiludronique |
| Time zone syndrome |
Jet lag (finding) |
| Timed unsupported steady stand test (procedure) |
Timed unsupported steady stand time |
| Timolol maleate 0.25% ophthalmic solution (product) |
Timolol (as timolol maleate) 2.5 mg/mL eye drops |
| Timolol maleate 0.5% (product) |
Product containing precisely timolol (as timolol maleate) 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
| Timolol maleate 0.5% ophthalmic solution (product) |
Product containing precisely timolol (as timolol maleate) 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
| Timolol maleate+bendroflumethiazide (product) |
Product containing bendroflumethiazide and timolol (medicinal product) |
| Tiotropium 18microgram inhalation powder capsule (product) |
Tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation |
| Tiotropium 18microgram inhalation powder capsule with device (product) |
Tiotropium (as tiotropium bromide) 18 microgram/actuation powder for inhalation |
| Tis (0): Carcinoma in situ (limited to fallopian tube mucosa) (finding) |
cTis |
| Tis (0): Carcinoma in situ (vagina) (finding) |
cTis |
| Tis category (finding) |
cTis |
| Tis: Carcinoma in situ ("flat tumor" of urinary bladder) (finding) |
cTis |
| Tis: Carcinoma in situ (endometrium/uterine cervix) |
cTis |
| Tis: Carcinoma in situ (finding) |
cTis |
| Tis: Epithelium only (carcinoma in situ, no invasion) (finding) |
cTis |
| Tis: Intratubular germ cell neoplasia (carcinoma in situ, testis) (finding) |
cTis |
| Tis: Tumor invades lamina propria (gastrointestinal tumor) (finding) |
American Joint Committee on Cancer cTis(LAMN) (qualifier value) |
| Tis: Tumor invades muscularis mucosae (colon/rectum) (finding) |
cTis |
| Tissue culture for chromosome analysis, more complex procedure with special extra counts (procedure) |
Chromosome analysis |
| Tissue kallikrein |
Kininogen |
| Tissue processing technique, complex, embed, cut and stain, per autopsy (procedure) |
technique de traitement du tissu |
| Tissue processing technique, complex, embed, cut and stain, per surgical specimen |
technique de traitement du tissu |
| Titanium dioxide 20% paste (product) |
Product containing only titanium dioxide (medicinal product) |
| Tobacco dependence with current use (disorder) |
Tobacco dependence syndrome |
| Tobramycin 0.3%/fluorometholone 0.1% ophthalmic suspension (product) |
Product containing precisely fluorometholone acetate 1 milligram/1 milliliter and tobramycin 3 milligram/1 milliliter conventional release eye suspension (clinical drug) |
| Tobramycin 1.2g powder for injection solution vial (product) |
Tobramycin (as tobramycin sulfate) 1.2 g powder for solution for injection vial |
| Tobramycin 1.2mg/mL injection (product) |
Tobramycin (as tobramycin sulfate) 1.2 g powder for solution for injection vial |
| Tobramycin 300mg/5mL nebulizer solution (product) |
Tobramycin 60 mg/mL solution for inhalation |
| Tobramycin 60mg/mL solution (product) |
Tobramycin 60 mg/mL solution for inhalation |
| Tocilizumab 20mg/mL conventional release solution for injection (product) |
Tocilizumab only product in parenteral dose form |
FHIR